

MICROBIOME R&D AND BUSINESS COLLABORATION CONGRESS



10-11 OCTOBER 2024

WYNDHAM GRAND
ZHAOQING
DOWNTOWN

Organised by:



Co-hosted with:



WWW.GLOBAL-ENGAGE.COM

Hello & Welcome

Welcome to Global Engage's inaugural microbiome event in China, **Microbiome R&D and Business Collaboration Congress**, taking place in-person on the 10th and 11th of October 2024 at Wyndham Grand Zhaoqing Downtown, Zhaoqing, China.

Co-hosted with the Handsome Investment Group, this edition is an excellent platform for researchers and product developers to gain knowledge and explore strategies to turn discoveries into products. It aims to connect the community with investors for commercialization support and provides networking opportunities.

Running on multiple tracks, this conference will showcase unique areas of scientific and business developments in the skin microbiome and microbiome spaces. Key thought leaders will share the latest cutting-edge research, emerging technologies, commercial interest, product development, and regulatory & claim considerations.

Attend this conference to learn from leading scientists, showcase research, and explore industry partnerships and funding. It is an event of utmost importance that you should not miss.

We look forward to seeing you in Zhaoqing, China!

With warm wishes,



Wen Fang Woo

Conference Producer - ASIA

About the Event

Conference synopsis

SKIN MICROBIOME

- Skin microbiome & cosmeceuticals
- Skin health, wellbeing, and microbiome-associated skin disease
- Regulatory landscapes & consumer insights
- Skin immunology
- Latest advances on mapping and profiling technologies
- Role of skin microbiome in precision health
- Aging
- Hair & scalp
- Wound healing

MICROBIOME

- Gut microbiome in health & disease
- Beyond gut & women's health
- Microbiome translational medicine
- Microbiome therapeutics & regulatory & commercialisation
- Microbiome & cancer
- Microbiome data & tools
- Microbiome & pro/pre/postbiotics
- Personalised nutrition and HMO & infant

Poster Presentations

Poster presentation sessions will take place in breaks and alongside the other breakout sessions of the conference. Your presentation will be displayed in a dedicated area, with the other accepted posters from industry and academic presenters. In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration).

Poster competition

Poster winners will receive cash prizes worth USD 500 each, with a total of 6 prizes up for grabs. 2 exceptional entries among the 6 will be selected for a 15-minute speaking position on the program. Representatives from solution provider organisations or experts already speaking on the program are not eligible to enter the competition but are welcome to present posters at the meeting as normal.

Flash talks

Three 5-minute flash talks are allocated for industry and start-up companies to present an overview of their research poster.

Submission instruction

Poster competition/ presentation abstract submission deadline is on 6th September 2024. Download poster presentation/competition form [HERE](#)

Contact: haley@global-engage.com for more inquiries

About the Event

Sponsorship:

For sponsorship opportunities, please reach out to reuben@global-engage.com

Pricing:

Delegate Fee- USD 250

Solution / Tech Provider Fee - USD 1,299

[Reserve your spot here](#)

Official conference/hotel venue:

Wyndham Grand Zhaoqing Downtown
No.13, Xinghu Road, Duanzhou District,
Zhaoqing, Guangdong, China

肇庆市七星岩温德姆至尊酒店
中国广东省肇庆市端州区星湖大道五段13号



Our Speakers



SAMUEL FORSTER
Associate Professor,
CSL Centenary Fellow



ALBERT DASHI
CSO & Co-Founder,
Sequential



SARAH AHANNACH
Project Manager &
Postdoctoral Researcher,
University of Antwerp



LAWRENCE WEISS
CEO, Symbiome



MARC GÜELL
ICREA Research Professor,
Pompeu Fabra University



TAN TENG-HERN LOH
Assistant Professor, University
of Nottingham Ningbo



WAI-KAY SETO
Clinical Professor,
The University of Hong Kong



JOHN COMMON
Deputy Executive Director and
Professor of Cutaneous
Inflammation and Microbiome,
A*STAR Skin Research Labs and
Newcastle University



QI SU
Assistant Professor
(Research), Chinese University
of Hong Kong



SIAM POPLUECHAI
Associate Professor, Mae Fah
Luang University



SIMON WANG
Probiotics Lead – Active Living,
Fonterra Group



ERIC HUANG CHUN-MING
Chief Scientific Advisor, Yunneng
Biotechnology Co., Ltd



WEILIAN HUNG
Director of Probiotics
Research Center, Yili
Innovation Center



MOHD HAFIZ ARZMI
Associate Professor,
International Islamic University
Malaysia



GRACE PARK
VP R&D, HelloBiome



HONGWEI ZHOU
Director, Zhujiang Hospital



YONG-LIANG ZHU
CEO & Founder, PrecisionBio Inc.



MAURICE VAN-STEENSEL
Professor, Nanyang
Technological University



JODI WOAN-FEI LAW
Assistant Professor, University
of Nottingham Ningbo



SENIOR REPRESENTATIVE
Danone



ANNALISA TERRANEGRA
Principal Investigator,
Sidra Medicine



YAN TAN
CEO, XBiome

0800-0830

Registration & Morning Coffee

0830-0835

Global Engage & Handsome Investment Group Welcome Address

Chairperson:

0835-0905

Keynote Presentation



JOHN COMMON

Deputy Executive Director and Professor of Cutaneous Inflammation and Microbiome, A*STAR Skin Research Labs and Newcastle University

THE SKIN MICROBIOME IN CHRONIC INFLAMMATORY SKIN DISEASES

The skin is home to millions of bacteria, fungi and viruses that make up the complex communities of our skin microbiota. The composition of these microbial communities differ depending on biogeographical skin location and can remain stable for years. Technological advances in sequencing have allowed researchers to investigate resident microbial population at high resolution providing valuable insights into disease pathogenesis. These culture-independent investigations of the skin microbiome is revealing a much more complex picture of the contribution of species and stains to disease pathogenesis and severity. One of the largest disruptors of our skin microbiome is the occurrence of inflammatory skin diseases such as atopic dermatitis and ichthyosis. With atopic dermatitis being a disorder that effects 1 in 5 children, studies of the skin microbiome is particularly important when considering the paediatric phase of life. Recent studies are unraveling the mechanisms of host-microbe interplay at the skin barrier. Understanding the microbes and their collective contribution to skin health is important for the development of novel therapeutic approaches and interventions for improved relationships with our closest neighbours.

0905-0935

Keynote Presentation

Invitation Out

0935-1005

Solution Provider Presentation

For sponsorship opportunities, please contact reuben@global-engage.com

1005-1055


Morning Refreshments | Poster Presentations | 1-2-1 Meetings

MICROBIOTA & SKIN DISEASE

MICROBIOME DATA & TOOLS

Chairperson:

1055-1115



MAURICE VAN-STEENSEL

Professor, Nanyang Technological University

THE CASE FOR SELECTIVE MICROBIOME CONTROL



SAMUEL FORSTER

Associate Professor, CSL Centenary Fellow

INTEGRATING EXPERIMENTAL AND COMPUTATIONAL METHODS

The human gastrointestinal microbiome and the direct impact on immune state and human health more broadly has emerged as a compelling target for

1115-1135



MARC GÜELL
ICREA Research Professor, Pompeu Fabra University

MODULATING THE HOST SKIN USING THE SKIN MICROBIOME

We will present our advancements in transforming *Cutibacterium acnes* into a synthetic biology platform tailored for skin applications. Initially, our focus was on leveraging this bacterium to achieve sustained alterations in the skin's microbiome, utilizing natural variants. The stable environment of its natural habitat, the sebaceous appendices, provides a robust foundation for persistent bioengineering. Our efforts led to notable successful colonization and interesting therapeutic effects.

In recent years, our work has expanded to include the development of robust tools for the precise genetic manipulation of *C. acnes*. This includes a variety of synthetic biology components, circuit designs, and methodologies for genetic modification. Notably, we have developed several biocontainment approaches for controlled application of genetically altered bacteria. We have engineered and characterized the effectiveness of various synthetic functions, such as sebum regulation, immune system interaction, and sensing.

Our vision is to introduce new functions to human skin by engineering these endogenous microbes.

therapeutic intervention. Opportunities to develop new treatments for diseases from infections to cancers and inflammatory diseases are now clear; however, these opportunities remain constrained by fundamental technological limitations. We combine culture informed metagenomic analysis using our newly developed expam tool and advanced culturing methodologies with genome scale modelling, metabolic exchange scores and redundancy index to characterise the microbiome stability and subsequent disease state within a paediatric inflammatory bowel disease cohort. This approach and associated technologies have provided key understandings of host-microbiome interaction during disease state and supported development of live biotherapeutics for human applications.



QI SU
Assistant Professor (Research), The Chinese University of Hong Kong

GUT MICROBIOME MEETS ARTIFICIAL INTELLIGENCE

Artificial Intelligence (AI) is a powerful tool for gut microbiome. We explored the potential of AI with its application in the crosstalk between gut dysbiosis and Long COVID. We found that gut microbiome during the acute SARS-CoV-2 infection is related to the emergence of Long COVID after viral clearance, and based on this we built a regression model that predicts the length of the viral positive period, a binary model that predicts the risk of Long COVID, a multi-label model that predicts different symptoms, and a multi-class model that distinguishes Long COVID from common human diseases. Our series of studies revealed the significance of AI in understanding the role of gut microbiota in the pathogenesis, diagnosis and therapeutics of Long COVID and provided novel insights into the potential of gut microbiome-targeted applications for Long COVID in the post-COVID era.

1135-1150

EARLY CAREER RESEARCHER

This session is allocated for early career researchers to showcase their research at this conference. Please contact wenfang@global-engage.com to submit your interest

EARLY CAREER RESEARCHER

This session is allocated for early career researchers to showcase their research at this conference. Please contact wenfang@global-engage.com to submit your interest

1150-1210



JODI WOAN-FEI LAW
Assistant Professor, University of Nottingham Ningbo

THE GUT-SKIN AXIS: GUT MICROBIOME CONNECTIONS TO ATOPIC DERMATITIS (ECZEMA)

Atopic dermatitis (AD) is the most prevalent chronic inflammatory skin disease that manifests early in life, impacting 15–30% of children and 10% of adults. AD typically starts in childhood, with 60% of patients <1 year of age developing the disease. Recent advancements in research have shed light on the intricate relationship between the gut microbiome and the development of AD, thus, elucidating the concept of the gut-skin axis. Infancy and childhood are critical periods for the development of the gut microbiome, which in turn influences immune system maturation that shapes an individual’s disposition to AD. This bidirectional communication highlights the dynamic complexity of the body’s ecosystem, where perturbations in the gut microbiome can have profound implications on skin health and disease manifestation. This presentation delves into the burgeoning field of research investigating the relationships between the gut microbiome and AD, aiming to understand the underlying mechanisms and potential therapeutic avenues.

Senior Representative (Reserved)

1210-1240

Solution Provider Presentation

For sponsorship opportunities, please contact reuben@global-engage.com

Solution Provider Presentation

For sponsorship opportunities, please contact reuben@global-engage.com

1240-1340

Lunch | Poster Presentations | 1-2-1 Meetings

WOMEN’S & INFANT HEALTH

PROBIOTICS | PERSONALISED NUTRITION | HMO

Chairperson:

Chairperson:

1340-1400



SARAH AHANNACH
Project Manager & Postdoctoral Researcher, University of Antwerp

LACTOBACILLI ON INTIMATE SKIN MICROBIOME IN ISALA CITIZEN SCIENCE PROJECT



WEILIAN HUNG
Director of Probiotics Research Center, Yili Innovation Center

THE DEVELOPMENT AND APPLICATION OF NATIVE PROBIOTIC STRAINS IN CHINA

Lactobacilli are highly abundant in the vaginal microbiome but are also found on the skin, although in much lower abundances. In our large-scale citizen science project, Isala (<https://isala.be/en/>), we investigated the occurrence of lactobacilli on intimate skin areas. 275 women provided detailed surveys and swabs from various intimate skin sites. Here, we found that the skin microbiome around the mouth and the groin skin constitute of a mixture of typical skin bacteria as well as bacteria present in the saliva and the vagina respectively. Surprisingly, we also observed a higher relative abundance of typical vaginal lactobacilli, i.e. *Lactobacillus crispatus* and *Lactobacillus iners*, on the skin around the breasts compared to publicly available data of other skin sites that are also not in direct contact with vaginal fluid. These results suggest a stochastic dispersal of vaginal lactobacilli onto intimate skin sites. Our study is not only highly relevant for skin health, intimate hygiene practices such as vaginal douching, pubic shaving, underwear and menstrual products development, but also on offering a novel perspective on the dynamics between vaginal and skin microbiomes.

In recent years, the overall probiotic fever continues to intensify, and the global probiotic market is advancing steadily and rapidly. It is anticipated that the global market scale of probiotics will reach 111.5 billion US dollars by 2030. From the aspect of the regional market situation, the consumption scale of probiotics in the Asia-Pacific region holds the highest proportion in the world. The structure of the aging and the young has turned into the main potential battleground for the future development of probiotics in China. In response to the market and consumer demands, Yili Probiotic Research Center pools the strength from the upper, middle, and lower reaches of strain research and development, takes the research and development of Chinese patented probiotics as the direction, and is dedicated to exploring probiotics that are more suitable for the Chinese people.


1400-1420

CECILIA LI XI (Reserved)
Head of Clinical, Translational Science, Johnson & Johnson



SIMON WANG
Probiotics Lead – Active Living, Fonterra Group

1420-1440



SENIOR REPRESENTATIVE
Danone



ANNALISA TERRANEGRA
Principal Investigator, Sidra Medicine
THE GUT MICROBIOTA AS BIOMARKER OF CLINICAL OUTCOMES IN THE CONTEXT OF TYPE 1 DIABETES

Type 1 diabetes (T1D) is one of the common pediatric diseases in Qatar. In a cross-sectional study of 102 pediatric T1D patients, we searched for potential microbial biomarkers of clinical outcomes and explored the role of diet in modulating the biomarkers. Briefly, the genus Akkermansia, a mucin-degrading bacterium, was significantly elevated in the Qatari patients with poorly controlled HbA1c levels (>7.5%) and consuming an Arabic diet. A distinct microbial signature has been associated with high blood pressure (BP>90th percentile), characterized by a reduced Bifidobacterium genus.

1440-1510

Solution Provider Presentation

For sponsorship opportunities, please contact reuben@global-engage.com

An integrated analysis of the nutrient intake, gut microbiome, and blood transcriptome discriminated T1D-obese patients (BMI>95th percentile) from non-diabetic obese children. These findings show the strong potential of the gut microbiota as a biomarker of clinical outcomes and will pose the basis for microbiome-based therapies for T1D.

Solution Provider Presentation

For sponsorship opportunities, please contact reuben@global-engage.com

1510-1600

Afternoon Refreshments | Poster Presentations | 1-2-1 Meetings

Chairperson:

1600-1615

Flash Presentations

Three 5-minute flash talks are allocated for industry and start-up companies to present an overview of their research

1615-1700

Panel Discussion

COMMERCIALISATION: SCIENCE VERSUS CONSUMERS

- Recent advances
- Strategies for bringing products to market
- Application and regulations
- Consumer
- Future direction

1705

End of Day 1 | Dinner Reception

All delegates are welcome to join the dinner reception

0800-0855

Registration & Morning Coffee

Chairperson:

0900-0930

Keynote Presentation



LAWRENCE WEISS
CEO, Symbiome

BACK TO HEALTH - AN EVOLUTIONARY BIOLOGY PERSPECTIVE ON THE SKIN MICROBIOME

Major Points

- Metagenomics and metabolomics of the Yanomami skin microbiome.
- Functional anatomy of the ancestral skin microbiome.
- Translating the ancestral skin microbiome into safe and effective interventions.

The emerging science of the microbiome is still in its infancy, yet it is the driving force behind a transformative scientific revolution. What lies ahead will have broad implications for us as scientists, our companies and academic institutions, our health, and perhaps our survival. It is worth reflecting on where we are today, how we got here, what we have learned so far, and the limitations of our methods and of our vision. I will discuss what we are learning about our biological past from the microbiota of minimally impacted hunter-gatherers and how it challenges our deeply held ideas about human health that may inform our path forward.

0930-1000

Keynote Presentation



HONGWEI ZHOU
Director, Zhujiang Hospital

1000-1030

Solution Provider Presentation

For sponsorship opportunities, please contact reuben@global-engage.com

1030-1120

Morning Refreshments | Poster Presentations | 1-2-1 Meetings

COMPANY SPOTLIGHT

MICROBIOME IN HEALTH AND DISEASE - GUT & BEYOND

Chairperson:

Chairperson:

1120-1140

SENIOR REPRESENTATIVE
Handsome investment Group



WAI-KAY SETO
Clinical Professor, The University of Hong Kong
THE GUT MICROBIOME AND THE LIVER: THE PRESENT AND THE FUTURE

1140-1200



GRACE PARK
VP R&D, HelloBiome

REDEFINING SKIN TYPES THROUGH AI: MICROBIOME-BASED SEGMENTATION FOR PRODUCT INNOVATION AND PERSONALIZATION

The dynamic interplay between the skin microbiome and personal care products is multifaceted and intricate. While these products aim to cleanse, beautify, and protect, they can sometimes disturb the delicate balance of skin microbes, leading to dysbiosis. Recognizing the importance of the microbiome's influence on skin health, our study recruited 1000 participants who completed detailed skin and lifestyle questionnaires and collected skin microbiome samples at home. Through a comprehensive analysis, we observed distinct skin microbiome profiles, classifying various skin types into clusters based on their predominant microbial species, such as Cutibacterium, Corynebacterium, Staphylococcus, and Streptococcus. Our formulating strategy targeted these microorganisms linked to specific skin conditions within each cluster. Our method went beyond selecting active ingredients that modify microbial populations; we carefully adjusted product pH and moisture levels and chose suitable preservatives and ingredients, crafting bespoke solutions for each unique skin profile.

1200-1230

Solution Provider Presentation

For sponsorship opportunities, please contact: reuben@global-engage.com

The gut microbiome has been linked to many aspects of human health, including the liver. This talk will review the latest findings on the gut-liver axis, including the role of the microbiome in liver metabolism, inflammation, and in various chronic liver diseases, including viral hepatitis, metabolic associated fatty liver disease, liver cirrhosis and liver cancer. We will also discuss emerging strategies for manipulating the gut microbiome to promote liver health, such as probiotics, and fecal microbiota transplantation. The presentation aims to provide a comprehensive overview of this burgeoning field, emphasizing the importance of understanding the gut microbiome's impact on liver health and disease management.



MOHD HAFIZ ARZMI
Associate Professor, International Islamic University Malaysia

HARNESSING THE POWER OF BIOTICS: INNOVATIONS IN ORAL MICROBIOME MANAGEMENT FOR OPTIMAL HEALTH

Probiotics, prebiotics, and postbiotics are revolutionizing oral health care, offering cutting-edge solutions for preventing and managing oral diseases. Probiotics, composed of live beneficial bacteria, inhibit harmful pathogens, reducing incidences of dental caries, periodontitis, and halitosis. Prebiotics, non-digestible fibers, selectively nourish these beneficial bacteria, fostering a robust and balanced oral microbiome. Postbiotics, the metabolic byproducts of probiotics, exhibit powerful antimicrobial, anti-inflammatory, and immunomodulatory properties, further enhancing oral health. This triad of biotics not only disrupts pathogenic biofilms but also promotes oral tissue health and systemic immunity. The integration of these biotics into oral care products represents a paradigm shift towards natural, holistic, and effective dental therapies. At this congress, he will present the latest research, technological advancements, and potential applications of probiotics, prebiotics, and postbiotics, heralding a new era in oral health that is both scientifically groundbreaking and clinically transformative.

Solution Provider Presentation

For sponsorship opportunities, please contact: reuben@global-engage.com

1230-1250



ALBERT DASHI
CSO & Co-Founder, Sequential



SIAM POPLUECHAI
Associate Professor, Mae Fah Luang University

A TRADITIONAL THAI MEDICINE INTERVENTION FOR NCDS TARGETS GUT

1250-1310



ERIC HUANG CHUN-MING
Chief Scientific Advisor, Yunneng Biotechnology Co., Ltd

SKIN S. EPIDERMIDIS, RIBOTYPES, PHENOTYPES AND BIO-ENGINEERING AS THERAPEUTICS

Different subtypes of *Staphylococcus epidermidis* (S. epidermidis) have been isolated from various resources in our laboratories. Ribotyping these S. epidermidis was conducted by deep learning neural network. Phenotyping these bacterial subspecies were achieved by biological assays in vitro and in vivo. Several SCFA-, carotenoids- and/or electrons-producing S. epidermidis was characterized. To non-genetically modify skin bacteria as bio-therapeutics, S. epidermidis bacteria were uploaded carotenoids (beta-carotene) on their membranes. Provision of external carotenoids to S. epidermidis substantially elevate the transcriptional expression of the NDH-2, and promote the electron production. Inoculation of carotenoid-laden bacteria onto the UV-irradiated mouse skin significantly diminished reactive oxygen species (ROS), demonstrating its beneficial effect on combating Redox imbalance. These carotenoids-laden S. epidermidis bacteria become new therapeutics for treatment of redox imbalance-associated human disorders such as cancer, aging, infection and inflammation.

Senior Representative (*Reserved*)

1310-1410

Lunch | Poster Presentations | 1-2-1 Meetings

HAIR & SCALP MICROBIOME | WOUND HEALING

MICROBIOME IN THERAPEUTICS DEVELOPMENT

Chairperson:

Chairperson:

1410-1425

Poster Winner Presentation


Poster winners will receive a cash prize worth USD 500 and a 15-minute speaking position on the program (eligible for non-vendor authors and registered delegates only)

Poster Winner Presentation

Poster winners will receive a cash prize worth USD 500 and a 15-minute speaking position on the program (eligible for non-vendor authors and registered delegates only)

1425-1445

Senior Representative (Reserved)
P&G



YAN TAN
CEO, XBiome

1445-1505



TAN TENG-HERN LOH
Assistant Professor, University of Nottingham Ningbo

INNOVATIVE WOUND DRESSINGS: USE OF PROBIOTICS FOR ENHANCED HEALING

The use of probiotics in wound dressings is emerging as a novel approach in the field of wound care. Probiotics, with their antimicrobial and anti-inflammatory properties, offer a unique advantage in promoting wound healing and preventing infections. This presentation delves into the development and application of probiotic-infused wound dressings, examining how these bioactive materials support the healing process. Key mechanisms include the suppression of pathogenic bacteria, enhancement of the skin's natural microbiome, and stimulation of tissue regeneration. Clinical trials and experimental studies demonstrating the effectiveness of probiotic dressings in accelerating wound closure and improving healing outcomes will be highlighted. This innovative approach has the potential to revolutionize wound care, offering a promising alternative to conventional treatments.



YONG-LIANG ZHU
CEO & Founder, PrecisionBio Inc

GENETICALLY ENGINEERED BACTERIA FOR THE TREATMENT OF HYPERURICEMIA

Hyperuricemia (HUA), i.e. increased serum uric acid (UA) concentration, is a common problem in clinical practice. It is estimated to occur in approximately 8.9% to 24.4% of the general population. HUA causes gout and it also plays a role in the pathogenesis of chronic kidney disease, hypertension, cardiovascular disease and heart failure. Currently treatments of HUA is inadequate as small molecule drugs in treating gout have severe side effects. We aim to develop live bacterial therapeutics in the management of HUA. E. coli Nissel 1917 was engineered to overexpress a fungi uricase. Engineered bacteria showed activity in breaking down uric acid in vitro. Furthermore, protein structure directed mutations were made for the uricase to have stronger UA breaking activity. A xanthine oxidase gene knockout was also carried out to block UA formation in engineered strains. Strains with different combinations of mutant genes and knockout showed different degree of UA lowering activity in in vitro or in vivo assays. One strain was selected for further development as it strongly lowered blood uric acid level in hyperuricemia model animals.

1505

End of Day 2

Additional Information

Transportation options:

By car/taxi from Guangzhou Baiyun International Airport ↔ hotel.

Taxis are abundant and easily accessible from the airport. It takes 1.5 hours to reach the hotel, with the cost ranging from approximately USD42 ~ USD55 per ride.

Car rentals - there are numerous rental car agencies throughout the region, with several located at the airport.

By metro/bullet train from Guangzhou Baiyun International Airport ↔ hotel

Disembark Guangzhou East Railway Station from airport T1 (Airport South Station) or T2 (Airport North Station) using metro line 3. The duration is about 37-min, with train interval of 7-min.

By taxi, the trip to Guangzhou East Railway Station takes about 40-min.

From Guangzhou East Railway Station, take a bullet train to Zhaoqing East Railway Station. This journey takes about 30 minutes. The hotel is 27 kilometers from Zhaoqing East Railway Station.

Discover Zhaoqing:

Zhaoqing located in the central-west part of Guangdong province, is one of the National Famous Historical and Cultural Cities and the Top Tourist Cities of China. Also known as the “capital of inkstones in China”, Zhaoqing is rich in tourism resources, where a long tourism corridor has been developed, with the Xinghu Scenic Area as the centre and numerous tourist attractions along Xijiang and Suijiang.

Admire the hundreds of Tang Dynasty inscriptions decorating the adjacent Seven Star Crag, check out the rare red-crowned cranes in Xinghu Wetland Park, and see the spectacular waterfall and Buddhist temple of Qingyun on a hike at Dinghu Mountain.



[Discover more](#)

Additional Information

Visa application:

If you are attending from a country requiring a visa, please be sure to apply early and complete all required fields. Applications may be denied if necessary information is not included when submitted. We recommend applying for your visa as early as possible.

[Learn more](#)

Visa exemption program:

From March 14, 2024 to December 31, 2025, China has decided to implement a unilateral visa-free policy for ordinary passport holders from twelve countries: **Germany, France, Italy, the Netherlands, Spain, Malaysia, Switzerland, Ireland, Hungary, Austria, Belgium and Luxembourg**. Citizens holding ordinary passports from the above countries who come to China for business, tourism, family visit and transit purposes for no more than 15 days can enter China without a visa. People from the above-mentioned countries who do not meet the conditions for visa exemption still need to apply for a visa before entering China.

[Learn more](#)

Invitation letter:

Please contact haley@global-engage.com to request an invitation letter needed to begin your visa application process.

Upcoming Events

25-26
OCT

**9th Microbiome R&D and Business
Collaboration Congress: Asia**

Bangkok, Thailand
Co-located with 4th ASEAN Gastro International Conference

2nd Spatial Biology Congress Asia

LKC School of Medicine, NTU, Singapore
Co-hosted with Genome Institute of Singapore,
A*STAR

21-22
NOV

MAR

**3rd Cell & Gene Therapy Research
& Development Congress Asia**

Singapore

**10th Microbiome R&D and Business
Collaboration Congress: Asia**

Singapore

MAY

JUL

2nd Single Cell Congress Asia

Singapore